Dolutegravir and Omeprazole Interaction

Drug interaction information between Dolutegravir and Omeprazole.

Dolutegravir and Omeprazole have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Dolutegravir and Omeprazole. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Dolutegravir

Integrase Strand Transfer Inhibitor

Drug B

Omeprazole

Proton Pump Inhibitor (PPI)

How They Interact

Omeprazole does not significantly change how the body processes dolutegravir, so the two drugs do not have a meaningful interaction.

FDA Label Information

Darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, tenofovir, boceprevir, prednisone, rifabutin, and omeprazole had no clinically significant effect on the pharmacokinetics of dolutegravir.

Frequently Asked Questions

What SPL severity band is on file for Dolutegravir + Omeprazole?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Dolutegravir has 28 labeled pairs on file vs Omeprazole's 27. In the minor band specifically: Dolutegravir has 21 (also Prednisone, Estradiol, Carbamazepine, Rifampin); Omeprazole has 22 (also Aripiprazole, Atomoxetine, Brexpiprazole, Carbamazepine).

What mechanism field is on file for Dolutegravir and Omeprazole?

Omeprazole does not significantly change how the body processes dolutegravir, so the two drugs do not have a meaningful interaction.

Dolutegravir's labeled portfolio outnumbers Omeprazole

SPL source-record counts only. This page's band is minor · classes on file: Dolutegravir (Integrase Strand Transfer Inhibitor); Omeprazole (Proton Pump Inhibitor (PPI)).

Dolutegravir

1 major · 6 moderate · 21 minor · 28 total

Omeprazole

1 major · 4 moderate · 22 minor · 27 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.